Increasing evidence has highlighted the oncogenic role of EIF4A1 in various cancers, including prostate, pancreatic, and breast cancer (Modelska et al., 2015; Ma et al., 2019; Wang et al., 2022). Here, EIF4A1 is linked to breast carcinoma.